Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35345
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTan, Daniel J-
dc.contributor.authorLodge, Caroline J-
dc.contributor.authorWalters, E Haydn-
dc.contributor.authorBui, Dinh S-
dc.contributor.authorPham, Jonathan-
dc.contributor.authorLowe, Adrian J-
dc.contributor.authorBowatte, Gayan-
dc.contributor.authorVicendese, Don-
dc.contributor.authorErbas, Bircan-
dc.contributor.authorJohns, David P-
dc.contributor.authorJames, Alan L-
dc.contributor.authorFrith, Peter-
dc.contributor.authorHamilton, Garun S-
dc.contributor.authorThomas, Paul S-
dc.contributor.authorWood-Baker, Richard-
dc.contributor.authorHan, MeiLan K-
dc.contributor.authorWashko, George R-
dc.contributor.authorAbramson, Michael J-
dc.contributor.authorPerret, Jennifer L-
dc.contributor.authorDharmage, Shyamali C-
dc.date.accessioned2024-06-21T06:27:09Z-
dc.date.available2024-06-21T06:27:09Z-
dc.date.issued2024-06-15-
dc.identifier.citationAmerican Journal of Respiratory and Critical Care Medicine 2024-06-15; 209(12)en_US
dc.identifier.issn1535-4970-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/35345-
dc.description.abstractRationale: The term "pre-chronic obstructive pulmonary disease" ("pre-COPD") refers to individuals at high risk of developing COPD who do not meet conventional spirometric criteria for airflow obstruction. New approaches to identifying these individuals are needed, particularly in younger populations. Objectives: To determine whether lung function thresholds and respiratory symptoms can be used to identify individuals at risk of developing COPD. Methods: The Tasmanian Longitudinal Health Study comprises a population-based cohort first studied in 1968 (at age 7 yr). Respiratory symptoms, pre- and post-bronchodilator (BD) spirometry, diffusing capacity, and static lung volumes were measured in a subgroup at age 45, and the incidence of COPD was assessed at age 53. For each lung function measure, z-scores were calculated using Global Lung Function Initiative references. The optimal threshold for best discrimination of COPD incidence was determined by the unweighted Youden index. Measurements and Main Results: Among 801 participants who did not have COPD at age 45, the optimal threshold for COPD incidence by age 53 was pre-BD FEV1/FVC z-score less than -1.264, corresponding to the lowest 10th percentile. Those below this threshold had a 36-fold increased risk of developing COPD over an 8-year follow-up period (risk ratio, 35.8; 95% confidence interval, 8.88 to 144), corresponding to a risk difference of 16.4% (95% confidence interval, 3.7 to 67.4). The sensitivity was 88%, and the specificity was 87%. Positive and negative likelihood ratios were 6.79 and 0.14, respectively. Respiratory symptoms, post-BD spirometry, diffusing capacity, and static lung volumes did not improve on the classification achieved by pre-BD FEV1/FVC alone. Conclusions: This is the first study, to our knowledge, to evaluate the discriminatory accuracy of spirometry, diffusing capacity, and static lung volume thresholds for COPD incidence in middle-aged adults. Our findings support the inclusion of pre-BD spirometry in the physiological definition of pre-COPD and indicate that pre-BD FEV1/FVC at the 10th percentile accurately identifies individuals at high risk of developing COPD in community-based settings.en_US
dc.language.isoeng-
dc.subjectCOPDen_US
dc.subjectdiffusing capacityen_US
dc.subjectlung volumesen_US
dc.subjectpre-COPDen_US
dc.subjectspirometryen_US
dc.titleCan We Use Lung Function Thresholds and Respiratory Symptoms to Identify Pre-Chronic Obstructive Pulmonary Disease? A Prospective, Population-based Cohort Study.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAmerican Journal of Respiratory and Critical Care Medicineen_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.;Monash Lung, Sleep, Allergy & Immunology, Monash Health, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.;Department of Basic Sciences, Faculty of Allied Health Sciences, University of Peradeniya, Peradeniya, Sri Lanka.en_US
dc.identifier.affiliationSchool of Psychology and Public Health, La Trobe University, Melbourne, Victoria, Australia.;Violet Vines Marshman Centre for Rural Health Research, La Trobe University, Bendigo, Victoria, Australia.en_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.;School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.en_US
dc.identifier.affiliationDepartment of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.en_US
dc.identifier.affiliationCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.en_US
dc.identifier.affiliationMonash Lung, Sleep, Allergy & Immunology, Monash Health, Melbourne, Victoria, Australia.;School of Clinical Sciences, and.en_US
dc.identifier.affiliationPrince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.en_US
dc.identifier.affiliationSchool of Medicine, University of Tasmania, Hobart, Tasmania, Australia.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.identifier.affiliationDivision of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Massachusetts.en_US
dc.identifier.affiliationSchool of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationAllergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.en_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.doi10.1164/rccm.202212-2330OCen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3536-8756en_US
dc.identifier.orcid0000-0002-4388-784Xen_US
dc.identifier.orcid0000-0001-7034-0615en_US
dc.identifier.pubmedid38236192-
dc.description.volume209-
dc.description.issue12-
dc.description.startpage1431-
dc.description.endpage1440-
dc.subject.meshtermssecondaryPulmonary Disease, Chronic Obstructive/physiopathology-
dc.subject.meshtermssecondaryPulmonary Disease, Chronic Obstructive/diagnosis-
dc.subject.meshtermssecondaryPulmonary Disease, Chronic Obstructive/epidemiology-
dc.subject.meshtermssecondarySpirometry/methods-
dc.subject.meshtermssecondaryTasmania/epidemiology-
dc.subject.meshtermssecondaryRespiratory Function Tests/methods-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptInstitute for Breathing and Sleep-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

110
checked on Nov 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.